ASN Kidney Week Early Programs – Glomerular Diseases: 2025 Update
$120.00
Early Program · Nephrology · 2025
This program delivers a glomerular diseases 2025 update through expert-led lectures and case conferences — covering IgA nephropathy, lupus nephritis, ANCA vasculitis, membranous nephropathy, complement therapy, and the emerging role of genetics and AI in glomerular diagnosis.
-
13videos
-
7 h 36 mtotal
-
2025year
- IgA nephropathy treatment selection among expanding options
- 2024 KDIGO lupus nephritis guideline updates
- Complement pathway targeting in glomerular disease
- Genetic testing and AI in glomerular diagnosis
Glomerular diseases in 2025 — new genetics, complement targets, and AI-driven diagnosis
Glomerular medicine is transforming rapidly, and this glomerular diseases 2025 update captures the latest across every major category — from choosing among expanding IgA nephropathy therapies to the 2024 KDIGO lupus nephritis guidelines, complement pathway targeting, and the emerging use of artificial intelligence in renal pathology. Faculty pair comprehensive updates with adult and pediatric case conferences, covering pathogenesis, novel diagnostics, and treatment algorithms that are reshaping clinical practice.
-
13video sessions
-
7 h 36 mtotal runtime
-
2025edition
Inside this resource
IgA nephropathy, lupus nephritis, and membranous nephropathy
A 45-minute session navigates the expanding landscape of IgA nephropathy treatment, comparing existing options and emerging agents. Lupus nephritis receives a dedicated KDIGO 2024 guideline update, while membranous nephropathy coverage addresses anti-PLA2R monitoring and rituximab-based protocols. Two extended clinicopathologic conferences — one nephritic, one nephrotic — apply these principles to complex real-world cases.
ANCA vasculitis, complement therapy, and podocytopathies
Faculty review current and future ANCA-associated vasculitis treatment strategies, including complement pathway targeting across glomerular diseases. A session on podocytopathies examines how antibody discovery is reshaping FSGS and minimal change disease classification. Monoclonal gammopathy of renal significance receives dedicated coverage with practical diagnostic and management approaches.
Genetics, AI, and type IV collagen diseases
A dedicated lecture on genetic testing in glomerular disease diagnosis and therapy addresses when and how to incorporate genetic panels into clinical decision-making. Alport syndrome and the broader spectrum of type IV collagen-related diseases receive comprehensive review. An artificial intelligence session explores how computational pathology is changing diagnostic accuracy in glomerular disease.
Who this serves
- Glomerular disease specialists — cutting-edge updates on diagnosis and emerging therapies
- General nephrologists — practical guidance on treatment selection and when to refer for genetic testing
- Pathologists — AI applications and evolving classification systems in glomerular pathology
The chart
| Format | Early Program · Videos + PDFs |
|---|---|
| Duration | 7 h 36 m across 13 sessions |
| Publisher | American Society of Nephrology |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout
6 reviews for ASN Kidney Week Early Programs – Glomerular Diseases: 2025 Update
Add a review
Related products
Nephrology
Nephrology
Ana B. –
Good breadth covering the full spectrum of glomerular disease. The podocytopathy classification session changed how I approach FSGS subtyping.
Mark J. –
Some sessions run long for the content covered. The lupus nephritis and ANCA vasculitis lectures were excellent, but the pacing varies noticeably.
Priya S. –
The AI in glomerular diagnosis session was eye-opening. Finally a practical look at how computational pathology changes day-to-day workflow.
Tom L. –
Strong program across the board. The clinicopathologic conferences were the highlight — real cases with expert-level discussion. Wished for more on C3 glomerulopathy specifically.
Rachel H. –
The IgA nephropathy treatment-selection lecture was outstanding. With so many new options, having a structured comparison was exactly what I needed.
Chen W. –
Comprehensive and up-to-date. The genetic testing lecture clarified exactly when to order panels versus when clinical diagnosis suffices.